Publications by authors named "T R Hawthorne"

Non-adherence to antipsychotic medications is a commonly recognized problem that can lead to lack of follow-up for patients with schizophrenia spectrum disorders, increasing risk for psychotic symptoms, hospitalizations, and decreased quality of life. We conducted a secondary data analysis of electronic health record data of patients with schizophrenia spectrum disorders ( = 1,341) in Central Florida to explore relationships between geographic access to mental healthcare facilities, socioeconomic factors, and follow-up visits, and whether these conditions contributed to adherence over 1 years' time. Using Geographic Information Systems among six mental health facilities, spatial analysis and logistic regression indicated that patients had 27.

View Article and Find Full Text PDF

Due to their low phase noise at high carrier frequencies, photonic microwave oscillators are continuously expanding their application areas including digital signal processing, telecommunications, radio astronomy, and RADAR and LIDAR systems. Currently, the lowest noise photonic oscillators rely on traditional optical frequency combs with multiple stabilization loops that incorporate large vacuum components and complex optoelectronic configurations. Hence, the resulting systems are not only challenging to operate but also expensive to maintain.

View Article and Find Full Text PDF
Article Synopsis
  • Chronic inducible urticaria (CIndU), a condition caused by mast cell-mediated allergic reactions, can be effectively treated with barzolvolimab, a humanized antibody that inhibits mast cell activation by stem cell factor (SCF).* -
  • In a trial involving patients unresponsive to antihistamines, one dose of barzolvolimab resulted in significant mast cell depletion and reduced levels of tryptase, leading to improved urticaria control and quality of life.* -
  • The treatment was well tolerated with mostly mild side effects, and 95% of patients showed complete responses within 12 weeks, indicating strong potential for barzolvolimab in treating mast cell-related disorders.*
View Article and Find Full Text PDF

Background: Phase 1/2 dose-escalation and expansion study evaluating varlilumab, a fully human agonist anti-CD27 mAb, with nivolumab in anti-PD-1/L1 naïve, refractory solid tumors.

Methods: Phase 1 evaluated the safety of varlilumab (0.1-10 mg/kg) with nivolumab (3 mg/kg) administered once every 2 weeks.

View Article and Find Full Text PDF

Predicting outcomes of marine disease outbreaks presents a challenge in the face of both global and local stressors. Host-associated microbiomes may play important roles in disease dynamics but remain understudied in marine ecosystems. Host-pathogen-microbiome interactions can vary across host ranges, gradients of disease, and temperature; studying these relationships may aid our ability to forecast disease dynamics.

View Article and Find Full Text PDF